Therapeutic effectiveness of upadacitinib on individual types of rash in Japanese patients with moderate‐to‐severe atopic dermatitis

红斑 医学 皮疹 皮肤病科 水肿 特应性皮炎 外科
作者
Teppei Hagino,Mai Yoshida,Risa Hamada,Eita Fujimoto,Hidehisa Saeki,Naoko Kanda
出处
期刊:Journal of Dermatology [Wiley]
卷期号:50 (12): 1576-1584 被引量:10
标识
DOI:10.1111/1346-8138.16950
摘要

Atopic dermatitis (AD) is a chronic eczematous disease with various types of rash, erythema, edema/papulation, excoriation, or lichenification. Janus kinase 1 inhibitor upadacitinib is effective for moderate-to-severe AD. We aimed to investigate the therapeutic effects of upadacitinib on each rash type in AD patients in real-world clinical practice. Seventy-two Japanese patients with moderate-to-severe AD were treated with oral upadacitinib 15 mg/day plus topical corticosteroids. The Eczema Area and Severity Index (EASI) scores for erythema, edema/papulation, excoriation, or lichenification on the whole body or on head and neck, upper limbs, lower limbs, or trunk were assessed at weeks 0, 4, and 12 of treatment. The proportions of patients who achieved resolution or at least 75% reduction of EASI from baseline (EASI 75) for individual rash types were calculated at weeks 4 and 12 on the whole body or each anatomical site. The resolution rates for excoriation, erythema, edema/papulation, or lichenification on the whole body were 38.3%, 23.7%, 21.7%, and 8.3% at week 4 and 18.3%, 18.6%, 11.6%, and 13.3% at week 12, respectively. The EASI scores for all rash types significantly decreased at weeks 4 and 12 compared to week 0. The achievement rates of EASI 75 for excoriation, erythema, edema/papulation, or lichenification on the whole body were 67.2%, 66.7%, 49.2%, and 37.7% at week 4 and 57.3%, 65%, 41%, and 41% at week 12, respectively. The achievement rate of EASI 75 for erythema on head and neck at week 4 (45.3%) was lower than that on upper limbs (71%) and on lower limbs (70.8%), and that on head and neck at week 12 (42.2%) was lower than that on lower limbs (69.2%). These results indicate that upadacitinib is effective for all AD rash types, especially for excoriation and erythema, while head-and-neck erythema might be less responsive to upadacitinib.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
山楂酱发布了新的文献求助10
1秒前
2秒前
2秒前
2秒前
2秒前
执着从灵完成签到 ,获得积分10
3秒前
Villanellel完成签到,获得积分10
4秒前
田様应助gsq采纳,获得30
5秒前
7秒前
wenbin发布了新的文献求助10
8秒前
8秒前
飘逸蘑菇完成签到 ,获得积分10
8秒前
ccc发布了新的文献求助20
12秒前
12秒前
12秒前
13秒前
善学以致用应助TaoBijiang采纳,获得10
14秒前
科研通AI5应助热情的达采纳,获得10
14秒前
量子星尘发布了新的文献求助10
14秒前
able发布了新的文献求助10
15秒前
淑文完成签到 ,获得积分20
16秒前
18秒前
天天快乐应助gj采纳,获得10
18秒前
昱珂完成签到,获得积分10
20秒前
20秒前
20秒前
21秒前
YYH完成签到,获得积分10
22秒前
从容冰夏发布了新的文献求助10
24秒前
bfs完成签到 ,获得积分10
24秒前
25秒前
momo发布了新的文献求助10
25秒前
wenbin完成签到,获得积分10
25秒前
好滴捏完成签到,获得积分20
26秒前
26秒前
26秒前
健康的涔完成签到,获得积分10
27秒前
姚世娇发布了新的文献求助10
28秒前
ccc完成签到,获得积分10
30秒前
大个应助WN采纳,获得10
30秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989334
求助须知:如何正确求助?哪些是违规求助? 3531428
关于积分的说明 11253936
捐赠科研通 3270119
什么是DOI,文献DOI怎么找? 1804887
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809173